Effects of phytochemicals on ionization radiation-mediated carcinogenesis and cancer therapy

Mutation Research - Reviews in Mutation Research

Volumn 728, Issue 3, 2011, Pages 139-157

  Nambiar, Dhanya ^a   Rajamani, Paulraj ^a   Singh, Rana P ^a,b  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

^b CENTRAL UNIVERSITY OF GUJARAT   (India)

Author keywords

Carcinogenesis; Phytochemicals; Radiation; Radiosensitization

Indexed keywords

ANTINEOPLASTIC AGENT; CAFFEIC ACID; CAMPTOTHECIN; CANAVANINE; CERAMIDE; CETUXIMAB; CURCUMIN; DIOSPYRIN; ELLAGIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR; FISETIN; FLAVOPIRIDOL; GENISTEIN; GOSSYPOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MALONALDEHYDE; NEEM OIL; PARTHENOLIDE; PLANT MEDICINAL PRODUCT; PLUMBAGIN; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PURINE NUCLEOTIDE; REACTIVE OXYGEN METABOLITE; RESVERATROL; SPHINGOMYELIN PHOSPHODIESTERASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; WITHAFERIN A;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRITIS; BLADDER CANCER; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL SURVIVAL; CHEMOPROPHYLAXIS; CHILDHOOD CANCER; CHROMOSOME ABERRATION; CHROMOSOME REARRANGEMENT; CLINICAL EFFECTIVENESS; COLON TUMOR; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DOUBLE STRANDED DNA BREAK; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SPECIFICITY; ENZYME INHIBITION; EPENDYMOMA; EPIGENETICS; ERYTHROLEUKEMIA CELL; EXCISION REPAIR; FEVER; GENE CONTROL; GENOMIC INSTABILITY; HETEROZYGOSITY LOSS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; LIPID PEROXIDATION; MIGRAINE; NONHUMAN; OXIDATIVE STRESS; PATIENT SAFETY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUALITY OF LIFE; RADIATION DOSE; RADIATION EXPOSURE; RADIATION INJURY; RADIOSENSITIVITY; REVIEW; SIGNAL TRANSDUCTION; SINGLE STRANDED DNA BREAK; SISTER CHROMATID EXCHANGE; STOMACH PAIN; TREATMENT RESPONSE; UTERINE CERVIX BIOPSY;

APOPTOSIS; CURCUMIN; DNA DAMAGE; ELLAGIC ACID; EPIGENESIS, GENETIC; GENISTEIN; NEOPLASMS; NEOPLASMS, RADIATION-INDUCED; PLANTS; RADIATION TOLERANCE; RADIATION, IONIZING; SIGNAL TRANSDUCTION;

EID: 80053587355     PISSN: 13835742     EISSN: 13882139     Source Type: Journal    
DOI: 10.1016/j.mrrev.2011.07.005     Document Type: Review

References (176)

1. Fontham E.T., Thun M.J., Ward E., Portier K.M., Balch A.J., Delancey J.O., Samet J.M. American Cancer Society perspectives on environmental factors and cancer. CA Cancer J. Clin. 2009, 59:343-351.
2. Little J.B. Radiation carcinogenesis. Carcinogenesis 2000, 21:397-404.
3. NCRP, Recommendations on Limits for Exposure to Ionizing Radiation, NCRP Report 91, National Council on Radiation Protection and Measurements, Bethesda, Maryland, 1987.
4. Haridasan P.P., Pillai P.M., Tripathi R.M., Puranik V.D. Occupational radiation exposure due to norm in a rare-earth compounds production facility. Radiat. Prot. Dosimetry 2008, 131:217-221.
5. Lawrence T.S., Randall K., Haken T., Giaccia A. Principles of radiation oncology. Cancer, Principles & Practice of Oncology 2005, 307-337. Lippincott Williams & Wilkins, Philadelphia. V.T. DeVita, S. Hellman, S.A. Rosenberg (Eds.).
6. Tobias J.S. Cancer of the head and neck. BMJ 1994, 308:961-966.
7. Riley P.A. Free radicals in biology: oxidative stress and the effects of ionizing radiation. Int. J. Radiat. Biol. 1994, 65:27-33.
8. DeLaney T.F., Trofimov A.V., Engelsman M., Suit H.D. Advanced-technology radiation therapy in the management of bone and soft tissue sarcomas. Cancer Control 2005, 12:27-35.
9. Steel G.G., Peckham M.J. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int. J. Radiat. Oncol. Biol. Phys. 1979, 5:85-91.
10. Hall E.J., Giaccia A.J. Radiobiology for the Radiologist 2006, Lippincott Williams & Wilkins, Philadelphia. sixth ed.
11. Caffo O. Radiosensitization with chemotherapeutic agents. Lung Cancer 2001, 34:S81-S90.
12. Brenner D.J., Hall E.J., Randers-Pehrson G., Miller R.C. Mechanistic considerations on the dose-rate/LET dependence of oncogenic transformation by ionizing radiation. Radiat. Res. 1993, 133:365-369.
13. Huang L., Snyder A.R., Morgan W.F. Radiation-induced genomic instability and its implications for radiation carcinogenesis. Oncogene 2003, 22:5848-5854.
14. Lorimore S.A., Coates P.J., Wright E.G. Radiation-induced genomic instability and bystander effects: inter-related non targeted effects of exposure to ionizing radiation. Oncogene 2003, 22:7058-7069.
15. Neijenhuis S., Verwijs-Janssen M., Kasten-Pisula U., Rumping G., Borgmann K., Dikomey E., Begg A.C., Vens C. Mechanism of cell killing after ionizing radiation by a dominant negative DNA polymerase beta. DNA Repair (Amst.) 2009, 8:336-346.
16. Lewanski C.R., Gullick W.J. Radiotherapy and cellular signalling. Lancet Oncol. 2001, 6:366-370.
17. Yang N., Chaudhary M.A., Wallace S.S. Base excision repair by hNTH1 and hOGG1: a two edged sword in the processing of DNA damage in gamma-irradiated human cells. DNA Repair (Amst.) 2006, 5:43-51.
18. Haimovitz-Friedman A., Kan C.C., Ehleiter D., Persaud R.S., McLoughlin M., Fuks Z., Kolesnick R.N. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J. Exp. Med. 1994, 180:525-535.
19. Yonei S., Furui H. Lethal and mutagenic effects of malonaldehyde, a decomposition product of peroxidized lipids, on Escherichia coli with different DNA repair capacities. Mutat. Res. 1981, 88:23-32.
20. Niedernhofer L.J., Daniels J.S., Rouzer C.A., Greene R.E., Marnett L.J. Malondialdehyde, a product of lipid peroxidation, is mutagenic in human cells. J. Biol. Chem. 2003, 278:31426-31433.
21. Richter C. Biophysical consequences of lipid peroxidation in membranes. Chem. Phys. Lipids 1987, 44:175-189.
22. Garrison W.M., Jayko M.E., Bennett W. Radiation-induced oxidation of protein in aqueous solution. Rad. Res. 1962, 16:483-502.
23. Garrison W.M. Reaction mechanisms in radiolysis of peptides, polypeptides, and proteins. Chem. Rev. 1987, 87:381-398.
24. Levine R.L. Carbonyl modifi{ligature}ed proteins in cellular regulation, aging, and disease. Free Radic. Biol. Med. 2002, 32:790-796.
25. Stadtman E.R., Levine R.L. Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids 2003, 3:207-218.
26. Zwick E., Bange J., Ullrich A. Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr. Relat. Cancer 2001, 8:161-173.
27. Contessa J.N., Abell A., Valerie K., Lin P.S., Schmidt-Ullrich R.K. ErbB receptor tyrosine kinase network inhibition radiosensitizes carcinoma cells. Int. J. Radiat. Oncol. Biol. Phys. 2006, 65:851-858.
28. Dittmann K., Mayer C., Fehrenbacher B., Schaller M., Raju U., Milas L., Chen D.J., Kehlbach R., Rodemann H.P. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J. Biol. Chem. 2005, 280:31182-31189.
29. Das A.K., Chen B.P., Story M.D., Sato M., Minna J.D., Chen D.J., Nirodi C.S. Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma. Cancer Res. 2007, 67:5267-5274.
30. Geoerger B., Gaspar N., Opolon P., Morizet J., Devanz P., Lecluse Y., Valent A., Lacroix L., Grill J., Vassal G. EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts. Int. J. Cancer 2008, 123:209-216.
31. Jing Z., Gong L., Xie C.Y., Zhang L., Su H.F., Deng X., Wu S.K. Reverse resistance to radiation in KYSE-150R esophageal carcinoma cell after epidermal growth factor receptor signal pathway inhibition by cetuximab. Radiother. Oncol. 2009, 93:468-473.
32. Cengel K.A., Voong K.R., Chandrasekaran S., Maggiorella L., Brunner T.B., Stanbridge E., Kao G.D., McKenna W.G., Bernhard E.J. Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells. Neoplasia 2007, 9:341-348.
33. Gupta A.K., McKenna W.G., Weber C.N., Feldman M.D., Goldsmith J.D., Mick R., Machtay M., Rosenthal D.I., Bakanauskas V.J., Cerniglia G.J., Bernhard E.J., Weber R.S., Muschel R.J. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin. Cancer Res. 2002, 8:885-892.
34. Albert J.M., Kim K.W., Cao C., Lu B. Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol. Cancer Ther. 2006, 5:1183-1189.
35. Xia S., Zhao Y., Yu S., Zhang M. Activated PI3K/Akt/COX-2 pathway induces resistance to radiation in human cervical cancer HeLa cells. Cancer Biother. Radiopharm. 2010, 3:317-323.
36. Cataldi A., Zauli G., Di Pietro R., Castorina S., Rana R. Involvement of the pathway phosphatidylinositol-3-kinase/AKT-1 in the establishment of the survival response to ionizing radiation. Cell Signal. 2001, 13:369-375.
37. Zheng L., Ren J.Q., Chen Q., Zhang H.P., Zhu H.G. The effect of HER2/neu overexpression on p53 gene expression, cell proliferation and sensitivity to gamma-irradiation via the PI3K/Akt pathway in breast cancer cell MCF7. Zhonghua Zhong Liu Za Zhi 2004, 26:594-597.
38. Kim T.J., Lee J.W., Song S.Y., Choi J.J., Choi C.H., Kim B.G., Lee J.H., Bae D.S. Increased expression of pAKT is associated with radiation resistance in cervical cancer. Br. J. Cancer 2006, 94:1678-1682.
39. Kao G.D., Jiang Z., Fernandes A.M., Gupta A.K., Maity A. Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation. J. Biol. Chem. 2007, 282:21206-21212.
40. Chen W.S., Lee Y.J., Yu Y.C., Hsaio C.H., Yen J.H., Yu S.H. Enhancement of p53-mutant human colorectal cancer cells radiosensitivity by flavonoid fisetin. Int. J. Radiat. Oncol. Biol. Phys. 2010, 77:1527-1535.
41. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., Ittmann M., Tycko B., Hibshoosh H. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 28:1943-1947.
42. Jiang Z., Pore N., Cerniglia G.J., Mick R., Georgescu M.M., Bernhard E.J., Hahn S.M., Gupta A.K., Maity A. Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. Cancer Res. 2007, 67:4467-4473.
43. Pattje W.J., Schuuring E., Mastik M.F., Slagter-Menkema L., Schrijvers M.L., Alessi S., van der Laan B.F., Roodenburg J.L., Langendijk J.A., van der Wal J.E. The phosphatase and tensin homologue deleted on chromosome 10 mediates radiosensitivity in head and neck cancer. Br. J. Cancer 2010, 102:1778-1785.
44. Rayet B., Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999, 18:6938-6947.
45. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999, 18:6853-6866.
46. Veuger S.J., Hunter J.E., Durkacz B.W. Ionizing radiation-induced NF-kappaB activation requires PARP-1 function to confer radioresistance. Oncogene 2009, 28:832-842.
47. Meng A., Yu T., Chen G., Brown S.A., Wang Y., Thompson J.S., Zhou D. Cellular origin of ionizing radiation-induced NF-kappaB activation in vivo and role of NF-kappaB in ionizing radiation-induced lymphocyte apoptosis. Int. J. Radiat. Biol. 2003, 79:849-861.
48. Brach M.A., Gruss H.J., Kaisho T., Asano Y., Hirano T., Herrmann F. Ionizing radiation induces expression of interleukin 6 by human fibroblasts involving activation of nuclear factor-kappa B. J. Biol. Chem. 1993, 25:8466-8472.
49. Janssens S., Tinel A., Lippens S., Tschopp J. PIDD mediates NF-kappaB activation in response to DNA damage. Cell 2005, 123:1079-1092.
50. Lee S.J., Dimtchev A., Lavin M.F., Dritschilo A., Jung M. A novel ionizing radiation-induced signaling pathway that activates the transcription factor, NF-kappaB. Oncogene 1998, 17:1821-1826.
51. Yakovlev V.A., Barani I.J., Rabender C.S., Black S.M., Leach J.K., Graves P.R. Tyrosine nitration of IkappaBalpha: a novel mechanism for NF-kappaB activation. Biochemistry 2007, 46:11671-11683.
52. Ahmed K.M., Li J.J. ATM-NF-kappaB connection as a target for tumor radiosensitization. Curr. Cancer Drug Targets 2007, 7:335-342.
53. Voboril R., Weberova-Voborilova J. Sensitization of colorectal cancer cells to irradiation by IL-4 and IL-10 is associated with inhibition of NF-kappaB. Neoplasma 2007, 54:495-502.
54. Chen X., Shen B., Xia L., Khaletzkiy A., Chu D., Wong J.Y., Li J.J. Activation of nuclear factor kappaB in radioresistance of TP53-inactive human keratinocytes. Cancer Res. 2002, 15:1213-1221.
55. Che S.M., Zhang X.Z., Hou L., Song T.B. Cyclooxygenase-2 inhibitor NS398 enhances radiosensitivity of radioresistant esophageal cancer cells by inhibiting AKT activation and inducing apoptosis. Cancer Invest. 2010, 28:679-688.
56. Davis T.W., O'Neal J.M., Pagel M.D., Zweifel B.S., Mehta P.P., Heuvelman D.M., Masferrer J.L. Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature. Cancer Res. 2004, 64:279-285.
57. Chen M.F., Wu C.T., Chen Y.J., Keng P.C., Chen W.C. Cell killing and radiosensitization by caffeic acid phenethyl ester (CAPE) in lung cancer cells. J. Radiat. Res. 2004, 45:253-260.
58. Kreus S., Siegmund D., Scheurich P., Wajant H. NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol.Cell. Biol. 2001, 21:3964-3973.
59. Bäumler C., Duan F., Onel K., Rapaport B., Jhanwar S., Offit K., Elkon K.B. Differential recruitment of caspase 8 to cFlip confers sensitivity or resistance to Fas-mediated apoptosis in a subset of familial lymphoma patients. Leuk. Res. 2003, 27:841-851.
60. Kim S., Lee T.J., Park J.W., Kwon T.K. Overexpression of cFLIPs inhibits oxaliplatin-mediated apoptosis through enhanced XIAP stability and Akt activation in human renal cancer cells. J. Cell. Biochem. 2008, 105:971-979.
61. Kataoka T., Budd R.C., Holler N., Thome M., Martinon F., Irmler M., Burns K., Hahne M., Kennedy N., Kovacsovics M., Tschopp J. The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways. Curr. Biol. 2000, 10:640-648.
62. Campbell K.J., Rocha S., Perkins N.D. Active repression of antiapoptotic gene expression by RelA(p65) NF-kB. Mol. Cell 2004, 13:853-865.
63. Kaltschmidt B., Kaltschmidt C., Hofmann T.G., Hehner S.P., Droge W., Schmitz M.L. The pro- or anti-apoptotic function of NF-κB is determined by the nature of the apoptotic stimulus. Eur. J. Biochem. 2000, 267:3828-3835.
64. Haimovitz-Friedman A., Balaban N., McLoughlin M., Ehleiter D., Michaeli J., Vlodavsky I., Fuks Z. Protein kinase C mediates basic fibroblast growth factor protection of endo thelial cells against radiation-induced apoptosis. Cancer Res. 1994, 54:2591-2597.
65. Michael J.M., Lavin M.F., Watters D.J. Resistance to radiation-induced apoptosis in Burkitt's lymphoma cells is associated with defective ceramide signaling. Cancer Res. 1997, 57:3600-3605.
66. Santana P., Peña L.A., Haimovitz-Friedman A., Martin S., Green D., McLoughlin M., Cordon-Cardo C., Schuchman E.H., Fuks Z., Kolesnick R. Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell 1996, 86:189-199.
67. Bionda C., Hadchity E., Alphonse G., Chapet O., Rousson R., Rodriguez-Lafrasse C., Ardail D. Radioresistance of human carcinoma cells is correlated to a defect in raft membrane clustering. Free Radic. Biol. Med. 2007, 43:681-694.
68. Kumar A., Oskouian B., Fyrst H., Zhang M., Paris F., Saba J.D. S1P lyase regulates DNA damage responses through a novel sphingolipid feedback mechanism. Cell Death Dis. 2011, 2:e119.
69. Wolff R.A., Dobrowsky R.T., Bielawska A., Obeid L.M., Hannun Y.A. Role of ceramide-activated protein phosphatase in ceramide-mediated signal transduction. J. Biol. Chem. 1994, 269:19605-19609.
70. Kishikawa K., Chalfant C.E., Perry D.K., Bielawska A., Hannun Y.A. Phosphatidic acid is a potent and selective inhibitor of protein phosphatase 1 and an inhibitor of ceramide-mediated responses. J. Biol. Chem. 1999, 274:21335-21341.
71. Zhang Y., Yao B., Delikat S., Bayoumy S., Lin X.H., Basu S., McGinley M., Chan-Hui P.Y., Lichenstein H., Kolesnick R. Kinase suppressor of Ras is ceramide-activated protein kinase. Cell 1997, 89:63-72.
72. Seno J.D., Dynlacht J.R. Intracellular redistribution and modification of proteins of the Mre11/Rad50/Nbs1 DNA repair complex following irradiation and heat-shock. J. Cell. Physiol. 2004, 199:157-170.
73. Helleday T., Lo J., van Gent D.C., Engelward B.P. DNA doublestrand break repair: from mechanistic understanding to cancer treatment. DNA Repair (Amst.) 2007, 6:923-935.
74. Willmore E., Elliott S.L., Mainou-Fowler T., Summerfield G.P., Jackson G.H., O'Neill F., Lowe C., Carter A., Harris R., Pettitt A.R., Cano-Soumillac C., Griffin R.J., Cowell I.G., Austin C.A., Durkacz B.W. DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia. Clin. Cancer Res. 2008, 14:3984-3992.
75. Beskow C., Skikuniene J., Holgersson A., Nilsson B., Lewensohn R., Kanter K., Viktorsson K. Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86. Br. J. Cancer. 2009, 101:816-821.
76. Nagasawa H., Little J.B., Lin Y.F., So S., Kurimasa A., Peng Y., Brogan J.R., Chen D.J., Bedford J.S., Chen B.P. Differential role of DNA-PKcs phosphorylations and kinase activity in radiosensitivity and chromosomal instability. Radiat. Res. 2011, 175:83-89.
77. Du L., Zhou L.J., Pan X.J., Wang Y.X., Xu Q.Z., Yang Z.H., Wang Y., Liu X.D., Zhu M.X., Zhou P.K. Radiosensitization and growth inhibition of cancer cells mediated by an scFv antibody gene against DNA-PKcs in vitro and in vivo. Radiat. Oncol. 2010, 5:70.
78. Zhuang W., Li B., Long L., Chen L., Huang Q., Liang Z.Q. Knockdown of the DNA-dependent protein kinase catalytic subunit radiosensitizes glioma-initiating cells by inducing autophagy. Brain Res. 2011, 1371:7-15.
79. Singh-Gupta V., Joiner M.C., Runyan L., Yunker C.K., Sarkar F.H., Miller S., Gadgeel S.M., Konski A.A., Hillman G.G. Soy isofl{ligature}avones augment radiation effect by inhibiting APE1/Ref-1 DNA repair activity in non-small cell lung cancer. J. Thorac. Oncol. 2011, 6:688-698.
80. Ahn J.Y., Schwarz J.K., Piwnica-Worms H., Canman C.E. Threonine68 phospho-rylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res. 2000, 60:5934-5936.
81. Shimura T., Kakuda S., Ochiai Y., Nakagawa H., Kuwahara Y., Takai Y., Kobayashi J., Komatsu K., Fukomoto M. Acquired radioresistance of human tumor cells by DNA-PK/AKT/GSK3beta-mediated cyclin D1 overexpression. Oncogene 2010, 29:4826-4837.
82. Huang G., Wang H., Yang L.X. Enhancement of radiation-induced DNA damage and inhibition of its repair by a novel camptothecin analog. Anticancer Res. 2010, 30:937-944.
83. Hara T., Omura-Minamisawa M., Kang Y., Cheng C., Inoue T. Flavopiridol potentiates the cytotoxic effects of radiation in radioresistant tumor cells in which p53 is mutated or Bcl-2 is overexpressed. Int. J. Radiat. Oncol. Biol. Phys. 2008, 71:1485-1495.
84. Kumar A., Rao A.R., Kimura H. Radiosensitizing effects of neem (Azadirachta indica) oil. Phytother. Res. 2002, 16:74-77.
85. Ueda S., Masutani H., Nakamura H., Tanaka T., Ueno M., Yodoi J. Redox control of cell death. Antioxidants Redox Signal. 2002, 4:405-414.
86. Schumacker P.T. Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 2006, 10:175-176.
87. Lee J.M., Johnson J.A. An important role of Nrf2-ARE pathway in the cellular defense mechanism. J. Biochem. Mol. Biol. 2004, 37:139-143.
88. Miura M., Sasaki T. Role of glutathione in the intrinsic radioresistance of cell lines from a mouse squamous cell carcinoma. Radiat. Res. 1991, 126:229-236.
89. Jagetia G.C., Baliga M.S. Treatment with Alstonia scholaris enhances radiosensitivity in vitro and in vivo. Cancer Biother. Radiopharm. 2003, 18:917-929.
90. Kumar B., Joshi J., Kumar A., Pandey B.N., Hazra B., Mishra K.P. Radiosensitization by diospyrin diethylether in MCF-7 breast carcinoma cell line. Mol. Cell. Biochem. 2007, 304:287-296.
91. Rao S.K., Rao P.S., Rao B.N. Preliminary investigation of the radiosensitizing activity of guduchi (Tinospora cordifolia) in tumor-bearing mice. Phytother. Res. 2008, 22:1482-1489.
92. Spitz D.R., Azzam E.I., Li J.J., Gius D. Metabolic oxidation/reduction reactions and cellular responses to ionizing radiation: a unifying concept in stress response biology. Cancer Metastasis Rev. 2004, 23:311-322.
93. Iles K.E., Forman H.J. Macrophage signaling and respiratory burst. Immunol. Res. 2002, 26:95-105.
94. Wang R., Lin F., Wang X., Gao P., Dong K., Wei S.H., Cheng S.Y., Zhang H.Z. Suppression of Bcl-xL expression by a novel tumor-specific RNA interference system inhibits proliferation and enhances radiosensitivity in prostatic carcinoma cells. Cancer Chemother. Pharmacol. 2008, 61:943-952.
95. Streffer J.R., Rimner A., Rieger J., Naumann U., Rodemann H.P., Weller M. BCL-2 family proteins modulate radiosensitivity in human malignant glioma cells. J. Neurooncol. 2002, 56:43-49.
96. Lee J.U., Hosotani R., Wada M., Doi R., Kosiba T., Fujimoto K., Miyamoto Y., Tsuji S., Nakajima S., Nishimura Y., Imamura M. Role of Bcl-2 family proteins (Bax, Bcl-2 and Bcl-X) on cellular susceptibility to radiation in pancreatic cancer cells. Eur. J. Cancer 1999, 35:1374-1380.
97. Cao C., Mu Y., Hallahan D.E., Lu B. XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene 2004, 23:7047-7052.
98. Dai Y., Liu M., Tang W., DeSano J., Burstein E., Davis M., Peinta K., Lawerence T., Xu L. Molecularly targeted radiosensitization of human prostate cancer by modulating inhibitor of apoptosis. Clin. Cancer Res. 2008, 14:7701-7710.
99. Kuribayashi K., El-Deiry W.S. Regulation of programmed cell death by the p53 Pathway. Adv. Exp. Med. Biol. 2008, 615:201-221.
100. Chipuk J.E., Maurer U., Green D.R., Schuler M. Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell 2003, 4:371-381.
101. Chipuk J.E., Kuwana T., Bouchier-Hayes L., Droin N.M., Newmeyer D.D., Schuler M., Green D.R. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004, 303:1010-1014.
102. Bennett M., Macdonald K., Chan S.W., Luzio J.P., Simari R., Weissberg P. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 1998, 282:290-293.
103. Han J., Goldstein L.A., Hou W., Gastman B.R., Rabinowich H. Regulation of mitochondrial apoptotic events by p53-mediated disruption of complexes between antiapoptotic Bcl-2 members and Bim. J. Biol. Chem. 2010, 285:22473-22483.
104. Brock W.A., Milas L., Bergh S., Lo R., Szabó C., Mason K.A. Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase. Cancer Lett. 2004, 205:155-160.
105. Kim S.Y., Yang E.S., Lee Y.S., Lee J., Park J.W. Sensitive to apoptosis gene protein regulates ionizing radiation-induced apoptosis. Biochimie 2011, 93:269-276.
106. Bence A.K., Adams V.R., Crooks P.A. l-Canavanine as a radiosensitization agent for human pancreatic cancer cells. Mol. Cell. Biochem. 2003, 244:37-43.
107. Nasu S., Milas L., Kawabe S., Raju U., Newman R. Enhancement of radiotherapy by oleandrin is a caspase-3 dependent process. Cancer Lett. 2002, 185:145-151.
108. Ganesan A., Nolan L., Crabb S.J., Packham G. Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery. Curr. Cancer Drug Targets 2009, 9:963-981.
109. Kim H.J., Bae S.C. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am. J. Transl. Res. 2011, 3:166-179.
110. Kim I.A., No M., Lee J.M., Shin J.H., Oh J.S., Choi E.J., Kim I.H., Atadja P., Bernhard E.J. Epigenetic modulation of radiation response in human cancer cells with activated EGFR or HER-2 signaling: potential role of histone deacetylase 6. Radiother. Oncol. 2009, 92:125-132.
111. Kim G.D., Choi Y.H., Dimtchev A., Jeong S.J., Dritschilo A., Jung M. Sensing of ionizing radiation-induced DNA damage by ATM through interaction with histone deacetylase. J. Biol. Chem. 1999, 274:31127-31130.
112. Kao G.D., McKenna W.G., Guenther Matthew G., Muschel J.R., Lazar M.A., Yen T.J. Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response. J. Cell Biol. 2003, 160:1017-1027.
113. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 2006, 5:769-784.
114. Bump E.A., Malaker K. Radioprotectors: Chemical, Biological and Clinical Perspective 1998, CRC Press, Florida.
115. Surh Y.J. Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer 2003, 3:768-780.
116. Nagano J., Kono S., Preston D.L., Moriwaki H., Sharp G.B., Koyama K., Mabuchi K. Bladder-cancer incidence in relation to vegetable and fruit consumption: a prospective study of atomic-bomb survivors. Int. J. Cancer 2000, 86:132-138.
117. Citrin D., Cotrim A.P., Hyodo F., Baum B.J., Krishna M.C., Mitchell J.B. Radioprotectors and mitigators of radiation-induced normal tissue injury. Oncologist 2010, 15:360-371.
118. Lamson D.W., Brignall M.S. Antioxidants in cancer therapy; their actions and interactions with oncologic therapies. Altern. Med. Rev. 1999, 4:304-329.
119. Jindal A., Soyal D., Sancheti G., Goyal P.K. Radioprotective potential of Rosemarinus officinalis against lethal effects of gamma radiation: a preliminary study. J. Environ. Pathol. Toxicol. Oncol. 2006, 25:633-642.
120. Parshad R., Sanford K.K., Price F.M., Steele V.E., Tarone R.E., Keloff G.J., Boone C.W. Protective action of plant polyphenols on radiation-induced chromatid breaks in cultured human cells. Anticancer Res. 1998, 18:3263-3266.
121. Hu Y., Cao J.J., Liu P., Guo D.H., Wang Y.P., Yin J., Zhu Y., Rahman K. Protective role of tea polyphenols in combination against radiation-induced haematopoietic and biochemical alterations in mice. Phytother. Res. 2011, (Epub ahead of print). 10.1002/ptr.3483.
122. Badr F.M., El Habit O.H., Harraz M.M. Radioprotective effect of melatonin assessed by measuring chromosomal damage in mitotic and meiotic cells. Mutat. Res. 1999, 444:367-372.
123. Uma Devi P., Ganasoundari A., Vrinda B., Srinivasan K.K., Unnikrishnan M.K. Radiation protection by the ocimum flavonoids orientin and vicenin: mechanisms of action. Radiat. Res. 2000, 54:455-460.
124. Azuine M.A., Bhide S.V. Adjuvant chemoprevention of experimental cancer: catechin and dietary turmeric in forestomach and oral cancer models. J. Ethnopharmacol. 1994, 44:211-217.
125. Li M., Zhang Z., Hill D.L., Wang H., Zhang R. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res. 2007, 67:1988-1996.
126. Andrzejewski T., Deeb D., Gao X., Danyluk A., Arbab A.S., Dulchavsky S.A., Gautam S.C. Therapeutic efficacy of curcumin/TRAIL combination regimen for hormone-refractory prostate cancer. Oncol. Res. 2008, 17:257-267.
127. Binion D.G., Otterson M.F., Rafiee P. Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut 2008, 57:1509-1517.
128. Chearwae W., Bright J.J. 15-Deoxy-delta(12,14)-prostaglandin J(2) and curcumin modulate the expression of toll-like receptors 4 and 9 in autoimmune T lymphocyte. J. Clin. Immunol. 2008, 28:558-570.
129. Javvadi P., Segan A.T., Tuttle S.W., Koumenis C. The chemopreventive agent curcumin is a potent radiosensitizer of human cervical tumor cells via increased reactive oxygen species production and overactivation of the mitogen-activated protein kinase pathway. Mol. Pharmacol. 2008, 73:1491-1501.
130. Javvadi P., Hertan L., Kosoff R., Datta T., Kolev J., Mick R. Thioredoxin reductase-1 mediates curcumin-induced radiosensitization of squamous carcinoma cells. Cancer Res. 2010, 70:1941-1950.
131. Yallapu M.M., Maher D.M., Sundram V., Bell M.C., Jaggi M., Chauhan S.C. Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. J. Ovarian Res. 2010, 29:3-11.
132. Rafiee P., Binion D.G., Wellner M., Behmaram B., Floer M., Mitton E., Nie L., Zhang Z., Otterson M.F. Modulatory effect of curcumin on survival of irradiated human intestinal microvascular endothelial cells: role of Akt/mTOR and NF-{kappa}B. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 298:G865-G877.
133. Mendonca M.S., Chin-Sinex H., Gomez-Millan J., Datzman N., Hardacre M., Comerford K., Nakshatri H., Nye M., Benjamin L., Mehta S., Patino F., Sweeney C. Parthenolide sensitizes cells to X-ray-induced cell killing through inhibition of NF-kappaB and split-dose repair. Radiat. Res. 2007, 168:689-697.
134. Sun Y., St Clair D.K., Fang F., Warren G.W., Rangnekar V.M., Crooks P.A. The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-kappaB inhibition and enhanced by the presence of PTEN. Mol. Cancer Ther. 2007, 6:2477-2486.
135. Tergaonkar V., Pando M., Vafa O., Wahl G., Verma I. p53 stabilization is decreased upon NF-kappaB activation: a role for NF-kappaB in acquisition of resistance to chemotherapy. Cancer Cell 2002, 1:493-503.
136. Rocha S., Martin A.M., Meek D.W., Perkins N.D. p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-kappaB subunit with histone deacetylase 1. Mol. Cell Biol. 2003, 23:4713-4727.
137. Won Y.K., Ong C.N., Shen H.M. Parthenolide sensitizes ultraviolet (UV)-B-induced apoptosis via protein kinase C-dependent pathways. Carcinogenesis 2005, 26:2149-2156.
138. Watson C., Miller D.A., Chin-Sinex H., Losch A., Hughes W., Sweeney C. Suppression of NF-kappaB activity by parthenolide induces X-ray sensitivity through inhibition of split-dose repair in TP53 null prostate cancer cells. Radiat. Res. 2009, 171:389-396.
139. Sun Y., St Clair D.K., Xu Y., Crooks P.A., St Clair W.H.A. NADPH oxidase-dependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells. Cancer Res. 2010, 70:2880-2890.
140. Messina M.J., Persky V., Setchell K.D.R., Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr. Cancer 2009, 21:113-131.
141. Bronikowska J., Szliszka E., Czuba Z.P., Zwolinski D., Szmydki D., Krol W. The combination of TRAIL and isoflavones enhances apoptosis in cancer cells. Molecules 2010, 15:2000-2015.
142. Cappelletti V., Miodini P., Di Fronzo G., Daidone M.G. Modulation of estrogen receptor-beta isoforms by phytoestrogens in breast cancer cells. Int. J. Oncol. 2006, 28:1185-1191.
143. Johnson W.D., Dooley L., Morrissey R.L., Arp L., Kapetanovic I., Crowell J.A., McCormick D.L. Oncogenicity evaluations of chemopreventive soy components in p53(±) (p53 knockout) mice. Int. J. Toxicol. 2006, 25:219-228.
144. Bektic J., Guggenberger R., Eder I.E., Pelzer A.E., Berger A.P., Bartsch G. Molecular effects of the isoflavonoid genistein in prostate cancer. Clin. Prostate Cancer 2005, 4:124-129.
145. Schmidt F., Knobbe C.B., Frank B., Wolburg H., Weller M. The topoisomerase II inhibitor, genistein, induces G2/M arrest and apoptosis in human malignant glioma cell lines. Oncol. Rep. 2008, 19:1061-1066.
146. Zhou N., Yan Y., Li W., Wang Y., Zheng L., Han S., Yan Y., Li Y. Genistein inhibition of topoisomerase II alpha expression participated by Sp1 and Sp3 in HeLa cell. Int. J. Mol. Sci. 2009, 10:3255-3268.
147. Cao F., Jin T.Y., Zhou Y.F. Inhibitory effect of isoflavones on prostate cancer cells and PTEN gene. Biomed. Environ. Sci. 2006, 19:35-41.
148. Hermann R.M., Wolff H.A., Jarry H., Thelen P., Gruendker C., Rave-Fraenk M., Schmidberger H., Christiansen H. In vitro studies on the modification of low-dose hyper-radiosensitivity in prostate cancer cells by incubation with genistein and estradiol. Radiat. Oncol. 2008, 3:19.
149. Wang B.F., Wang J.S., Lu J.F., Kao T.H., Chen B.H. Antiproliferation effect and mechanism of prostate cancer cell lines as affected by isoflavones from soybean cake. J. Agric. Food Chem. 2009, 57:2221-2232.
150. Raffoul J.J., Banerjee S., Che M., Knoll Z.E., Doerge D.R., Abrams J., Kucuk O., Sarkar F.H., Hillman G.G. Soy isoflavones enhance radiotherapy in a metastatic prostate cancer model. Int. J. Cancer 2007, 120:2491-2498.
151. Yashar C.M., Spanos W.J., Taylor D.D., Gercel-Taylor C. Potentiation of the radiation effect with genistein in cervical cancer cells. Gynecol. Oncol. 2005, 99:199-205.
152. Zhang B., Liu J.Y., Pan J.S., Han S.P., Yin X.X., Wang B. Combined treatment of ionizing radiation with genistein on cervical cancer HeLa cells. J. Pharmacol. Sci. 2006, 102:129-135.
153. Singh-Gupta V., Zhang H., Banerjee S., Kong D., Raffoul J.J., Sarkar F.H. Radiation-induced HIF-1alpha cell survival pathway is inhibited by soy isoflavones in prostate cancer cells. Int. J. Cancer 2009, 124:1675-1684.
154. Oliver C.L., Miranda M.B., Shangary S., Land S., Wang S., Johnson D.E. (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance. Mol. Cancer Ther. 2005, 4:23-31.
155. Kasten-Pisula U., Windhorst S., Dahm-Daphi J., Mayr G., Dikomey E. Radiosensitization of tumour cell lines by the polyphenol Gossypol results from depressed double-strand break repair and not from enhanced apoptosis. Radiother. Oncol. 2007, 83:296-303.
156. Xu L., Yang D., Wang S., Tang W., Liu M., Davis M., Chen J., Rae J.M., Lawrence T., Lippman M.E. (-)-Gossypol enhances response to radiation therapy and results intumor regression of human prostate cancer. Mol. Cancer Ther. 2005, 4:197-205.
157. Susman E. Cottonseed-oil byproduct as anticancer radiation sensitiser. Lancet Oncol. 2004, 5:648.
158. Hayeshi R., Mutingwende I., Mavengere W., Masiyanise V., Mukanganyama S. The inhibition of human glutathione S-transferases activity by plant polyphenolic compounds ellagic acid and curcumin. Food Chem. Toxicol. 2007, 45:286-295.
159. Varadkar P., Dubey P., Krishna M., Verma N. Modulation of radiation-induced protein kinase C activity by phenolics. J. Radiol. Prot. 2001, 21:361-370.
160. Ang E.S., Pavlos N.J., Chai L.Y., Qi M., Cheng T.S., Steer J.H. Caffeic acid phenethyl ester, an active component of honeybee propolis attenuates osteoclastogenesis and bone resorption via the suppression of RANKL-induced NF-kappaB and NFAT activity. J. Cell. Physiol. 2009, 221:642-649.
161. Lin Y.H., Chiu J.H., Tseng W.S., Wong T.T., Chiou S.H., Yen S.H. Antiproliferation and radiosensitization of caffeic acid phenethyl ester on human medulloblastoma cells. Cancer Chemother. Pharmacol. 2006, 57:525-532.
162. Devi P.U., Sharada A.C., Solomon F.E. In vivo growth inhibitory and radiosensitizing effects of withaferin A on mouse Ehrlich ascites carcinoma. Cancer Lett. 1995, 16:189-193.
163. Sharada A.C., Solomon F.E., Devi P.U., Udupa N., Srinivasan K.K. Antitumor and radiosensitizing effects of withaferin A on mouse Ehrlich ascites carcinoma in vivo. Acta Oncol. 1996, 35:95-100.
164. Devi P.U., Kamath R., Rao B.S. Radiosensitization of a mouse melanoma by withaferin A: in vivo studies. Indian J. Exp. Biol. 2000, 38:432-437.
165. Uma Devi P., Utsumiz H., Takata M., Takeda S. Enhancement of radiation induced cell death in chicken B lymphocytes by withaferin A. Indian J. Exp. Biol. 2008, 46:437-442.
166. Yang S.J., Chang S.C., Wen H.C., Chen C.Y., Liao J.F., Chang C.H. Plumbagin activates ERK1/2 and Akt via superoxide, Src and PI3-kinase in 3T3-L1 cells. Eur. J. Pharmacol. 2003, 25:21-28.
167. Chen C.A., Chang H.H., Kao C.Y., Tsai T.H., Chen Y.J. Plumbagin, isolated from Plumbago zeylanica, induces cell death through apoptosis in human pancreatic cancer cells. Pancreatology 2009, 9:797-809.
168. Prasad V.S., Devi P.U., Rao B.S., Kamath R. Radiosensitizing effect of plumbagin on mouse melanoma cells grown in vitro. Indian J. Exp. Biol. 1996, 34:857-858.
169. Devi P.U., Rao B.S., Solomon F.E. Effect of plumbagin on the radiation induced cytogenetic and cell cycle changes in mouse Ehrlich ascites carcinoma in vivo. Indian J. Exp. Biol. 1998, 36:891-895.
170. Nair S., Nair R.R., Srinivas P., Srinivas G., Pillai M.R. Radiosensitizing effects of plumbagin in cervical cancer cells is through modulation of apoptotic pathway. Mol. Carcinog. 2008, 47:22-33.
171. Li Y., Liu J., Liu X., Xing K., Wang Y., Li F. Resveratrol-induced cell inhibition of growth and apoptosis in MCF7 human breast cancer cells are associated with modulation of phosphorylated Akt and caspase-9. Appl. Biochem. Biotechnol. 2006, 135:181-192.
172. Zoberi I., Bradbury C.M., Curry H.A., Bisht K.S., Goswami P.C., Roti J.L. Radiosensitizing and anti-proliferative effects of resveratrol in two human cervical tumor cell lines. Cancer Lett. 2002, 25:165-173.
173. Baatout S., Derradji H., Jacquet P., Ooms D., Michaux A., Mergeay M. Enhanced radiation-induced apoptosis of cancer cell lines after treatment with resveratrol. Int. J. Mol. Med. 2004, 13:895-902.
174. Liao H.F., Kuo C.D., Yang Y.C., Lin C.P., Tai H.C., Chen Y.Y. Resveratrol enhances radiosensitivity of human non-small cell lung cancer NCI-H838 cells accompanied by inhibition of NF-kappa B activation. J. Radiat. Res. 2005, 46:387-393.
175. Scarlatti F., Sala G., Ricci C., Maioli C., Milani F., Minella M. Resveratrol sensitization of DU145 prostate cancer cells to ionizing radiation is associated to ceramide increase. Cancer Lett. 2007, 253:124-130.
176. Kao C.L., Huang P.I., Tsai P.H., Tsai M.L., Lo J.F., Lee Y.Y., Chen Y.J., Chen Y.W., Chiou S.H. Resveratrol-induced apoptosis and increased radiosensitivity in CD133-positive cells derived from atypical teratoid/rhabdoid tumor. Int. J. Radiat. Oncol. Biol. Phys. 2009, 74:219-228.